ENANTA PHARMACEUTICALS INC (ENTA) intrinsic value & 10-year financials
ENANTA PHARMACEUTICALS INC (ENTA) has a Graham intrinsic value of $3.66 per share. At $11.10 on Oct 17, 2026, the stock trades 203% above that value. Over the last 10 fiscal years revenue shrank 3.3% a year to $65.3M, with an average return on invested capital of -24.4%.
- Graham intrinsic value
- $3.66
- Share price (Oct 17, 2026)
- $11.10
- Price vs Graham value
- 203% above
- Market cap
- $236.8K
- Revenue (FY2025)
- $65.3M
- Revenue growth (10-yr CAGR)
- -3.3%
- ROIC (10-yr avg)
- -24.4%
- Free cash flow (FY2025)
- -$32.2M
ENTA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $65.3M | -$81.9M | -$3.84 | -$32.2M | -130.7% | -71.9% |
| FY2024 | $67.6M | -$116.0M | -$5.48 | -$96.7M | -179.9% | -80.4% |
| FY2023 | $79.2M | -$133.8M | -$6.38 | -$112.2M | -173.2% | -60.7% |
| FY2022 | $86.2M | -$121.8M | -$5.91 | -$86.9M | -143.7% | -38.4% |
| FY2021 | $97.1M | -$79.0M | -$3.92 | -$70.7M | -112.9% | -22.5% |
| FY2020 | $122.5M | -$36.2M | -$1.81 | $5.6M | -34.0% | -11.2% |
| FY2019 | $205.2M | $46.4M | $2.21 | $66.0M | 17.9% | 8.6% |
| FY2018 | $206.6M | $72.0M | $3.48 | $26.2M | 42.7% | 19.6% |
| FY2017 | $102.8M | $17.7M | $0.91 | $50.1M | 23.9% | 5.7% |
| FY2016 | $88.3M | $21.7M | $0.00 | $31.1M | 34.9% | 7.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ENANTA PHARMACEUTICALS INC is facing top-line stagnation, with revenue contracting over the decade.
ENANTA PHARMACEUTICALS INC has historically struggled to out-earn its cost of capital, averaging just -24.4% ROIC.
Over the decade, ENANTA PHARMACEUTICALS INC shows that management has aggressively returned capital to shareholders by retiring 99.9% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ENANTA PHARMACEUTICALS INC is modeled at -3.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $3.66 per share.